Dec 12 2024 8 mins
Visit https://www.peervoice.com/JPM860 to view the entire programme with slides. After completing “Zaeem Siddiqi, MD, PhD - Tailoring Treatment for Hereditary Transthyretin Amyloidosis Polyneuropathy: The Evolution of Care”, participants will be able to: Evaluate the latest clinical evidence of RNA-targeted therapies for hereditary transthyretin amyloidosis with polyneuropathy (hATTR PN); Formulate individualized treatment plans based on disease and patient factors; and Summarize current and emerging data for transthyretin amyloid cardiomyopathy (ATTR CM).